Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volume
dc.contributor.author | Binkley, Michael S. | |
dc.contributor.author | Koenig, Julie L. | |
dc.contributor.author | Kashyap, Mehr | |
dc.contributor.author | Xiang, Michael | |
dc.contributor.author | Liu, Yufei | |
dc.contributor.author | Sodji, Quaovi | |
dc.contributor.author | Maxim, Peter G. | |
dc.contributor.author | Diehn, Maximilian | |
dc.contributor.author | Loo, Billy W., Jr. | |
dc.contributor.author | Gensheimer, Michael F. | |
dc.contributor.department | Radiation Oncology, School of Medicine | en_US |
dc.date.accessioned | 2020-07-30T19:45:38Z | |
dc.date.available | 2020-07-30T19:45:38Z | |
dc.date.issued | 2020-05-19 | |
dc.description.abstract | Background: We evaluated whether pre- and mid-treatment metabolic tumor volume (MTV) predicts per lesion local recurrence (LR) in patients treated with definitive radiation therapy (RT, dose≥60 Gy) for locally advanced non-small cell lung cancer (NSCLC). Methods: We retrospectively reviewed records of patients with stage III NSCLC treated from 2006 to 2018 with pre- and mid-RT PET-CT. We measured the MTV of treated lesions on the pre-RT (MTVpre) and mid-RT (MTVmid) PET-CT. LR was defined per lesion as recurrence within the planning target volume. Receiver operating characteristic (ROC) curves, cumulative incidence rates, and uni- and multivariable (MVA) competing risk regressions were used to evaluate the association between MTV and LR. Results: We identified 111 patients with 387 lesions (112 lung tumors and 275 lymph nodes). Median age was 68 years, 69.4% were male, 46.8% had adenocarcinoma, 39.6% had squamous cell carcinoma, and 95.5% received concurrent chemotherapy. Median follow-up was 38.7 months. 3-year overall survival was 42.3%. 3-year cumulative incidence of LR was 26.8% per patient and 11.9% per lesion. Both MTVpre and MTVmid were predictive of LR by ROC (AUC = 0.71 and 0.76, respectively) and were significantly associated with LR on MVA (P = 0.004 and P = 7.1e-5, respectively). Among lesions at lower risk of LR based on MTVpre, higher MTVmid was associated with LR (P = 0.001). Conclusion: Per-lesion, larger MTVpre and MTVmid predicted for increased risk of LR. MTVmid was more highly predictive of LR than MTVpre and if validated may allow for further discrimination of high-risk lesions at mid-RT informing dose painting strategies. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Binkley, M. S., Koenig, J. L., Kashyap, M., Xiang, M., Liu, Y., Sodji, Q., Maxim, P. G., Diehn, M., Loo, B. W., Jr, & Gensheimer, M. F. (2020). Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volume. Radiation oncology (London, England), 15(1), 114. https://doi.org/10.1186/s13014-020-01546-y | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/23454 | |
dc.language.iso | en_US | en_US |
dc.publisher | BMC | en_US |
dc.relation.isversionof | 10.1186/s13014-020-01546-y | en_US |
dc.relation.journal | Radiation Oncology | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.source | PMC | en_US |
dc.subject | FDG-PET | en_US |
dc.subject | Metabolic tumor volume | en_US |
dc.subject | Lung cancer | en_US |
dc.title | Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volume | en_US |
dc.type | Article | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 13014_2020_Article_1546.pdf
- Size:
- 1.14 MB
- Format:
- Adobe Portable Document Format
- Description:
- Main article
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.99 KB
- Format:
- Item-specific license agreed upon to submission
- Description: